Exchange: NASDAQ·Updated 06:43 PM EDT
ALKS logo

ALKSAlkermes plc

$51.94
$1.84
(3.42%)
Today
Closed $51.94
$0.9399
(1.81%)
After Hours
EarningsJul 28
Mkt Cap$8.66B
Vol1.69M
News
all
press releases
Arcturus Therapeutics (ARCT) Stock Jumps 5.7%: Will It Continue to Soar?
Arcturus Therapeutics (ARCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks
News Placeholder
More News
News Placeholder
Is HRMY Stock Worth Buying With Neutral Signals and Cheap Valuation?
Harmony Biosciences trades at discounted valuations, but investors are weighing Wakix dependence, recent earnings misses and pipeline execution.
Zacks
News Placeholder
HRMY Growth Trends Beyond Wakix Could Shape Its Next Growth Phase
Harmony Biosciences is broadening beyond Wakix with pitolisant programs, orexin research and rare epilepsy assets to diversify growth.
Zacks
News Placeholder
Micron To Rally Around 44%? Here Are 10 Top Analyst Forecasts For Thursday
Top analysts changed outlook on top names: Intuit downgraded, Alkermes price target raised, Carmax target increased, Sezzle target up, Biogen target raised, Progressive target cut.read more...
Benzinga
News Placeholder
Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026
Alkermes plc (Nasdaq: ALKS) today announced detailed positive results from the Vibrance-2 phase 2 dose-ranging study evaluating alixorexton in patients with narcolepsy type 2 (NT2). Once-daily alixorexton met the studys dual primary endpoints, demonstrating statistically significant and clinically...
Business Wire
News Placeholder
ALKS' Sleep Disorder Drug Gets Orphan Drug Tags in the U.S. & Europe
Alkermes wins orphan drug designations in the United States and Europe for alixorexton for treating idiopathic hypersomnia and narcolepsy, respectively.
Zacks
News Placeholder
Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe
Alkermes plc (Nasdaq: ALKS) today announced that alixorexton, a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH), was recently granted orphan drug...
Business Wire
News Placeholder
Why Is Revolution Medicines (RVMD) Up 9.3% Since Last Earnings Report?
Revolution Medicines (RVMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
News Placeholder
Alkermes (ALKS) Up 21.1% Since Last Earnings Report: Can It Continue?
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
News Placeholder
Alkermes to Present New Data on Alixorexton and LUMRYZ (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research
Alkermes plc (Nasdaq: ALKS) today announced plans to present new data from its industry-leading portfolio of sleep medicine research at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 14-17, 2026 in Baltimore, MD. The company will present...
Business Wire
<
1
2
...
>

Advertisement|Remove ads.